Kamada Ltd. (KMDA) Tops Q4 EPS by 26c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018
February 12, 2019 6:00 AM ESTTotal Revenues for Fiscal 2018 were $114.5 Million, up 11% Over Fiscal 2017; In-line with Recently Provided 2018 Expected Revenues of $113 Million and $115 Million Full-Year Proprietary Products Revenues up 14% Year-Over-Year Gross Profit for 2018 Grew 29% Year-Over-Year Adjusted EBITDA was $23.9 Million in 2018, an Increase of 109% Compared to $11.5 Million in 2017Reiterating Full-Year 2019 Total Revenue Guidance of $125 Million to $130 Million
REHOVOT, Israel, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced financial results for the three and 12-months ended December 31, 2018.
... More